GARDP study reveals that babies are increasingly dying of neonatal sepsis caused by drug-resistant bacterial infections

  27 April 2022

A large study focusing on newborn babies with clinically diagnosed sepsis has revealed the impact of antibiotic resistance on neonatal sepsis, a major cause of death in newborns.  

At the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), the Global Antibiotic Research and Development Partnership (GARDP) has released a second wave of findings from its study on the outcomes of more than 3,200 newborns with neonatal sepsis, a life-threatening bloodstream infection that affects up to 3 million babies a year. The study shows that an increasing number of babies die of resistant infections as the current treatments have become ineffective.  

The observational study, conducted by GARDP and key partners from 2018 to 2020, was carried out at 19 hospitals in 11 high-, middle- and low-income countries across four continents. It assessed which antibiotics are currently being used to treat newborns suffering from sepsis, and to what extent resistance makes these treatments ineffective. The aim of the study was to inform the development of improved antibiotic treatment regimens for neonatal sepsis worldwide. 

Further reading: GARDP
Author(s): GARDP
Effective Surveillance   Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!